Mycoplasma gallisepticum in Chickens: Chronic Respiratory Disease Diagnosis and Control

Introduction

Mycoplasma gallisepticum (MG) is a small, cell wall deficient bacterium belonging to the class Mollicutes. It is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys. MG infection causes substantial economic losses in commercial poultry operations through reduced egg production, increased feed conversion ratios, elevated mortality from secondary bacterial infections, and carcass condemnation at processing. The pathogen is transmitted vertically through the egg as well as horizontally via aerosol and fomites. Understanding the molecular mechanisms of pathogenesis, deploying accurate diagnostic platforms, and implementing rigorous control programs in breeder flocks remain central to MG management.

Pathogenesis and Host-Pathogen Interactions

MG colonizes the mucosal epithelium of the respiratory tract, trachea, and air sacs. The bacterium adheres to ciliated epithelial cells via surface adhesins such as GapA and CrmA, followed by the induction of ciliostasis and epithelial desquamation. The host inflammatory response is driven by activation of the MAPK pathway and upregulation of pro-inflammatory cytokines. Recent work has demonstrated that MG infection triggers TRPC1-STIM1/ORAI1 calcium channel signaling, leading to calcium influx and subsequent inflammation, a mechanism that can be attenuated by extracellular vesicles derived from Scutellaria baicalensis [9]. Additionally, the TatD nuclease of MG contributes to immune evasion and tissue damage, and the flavonoid luteolin has been shown to inhibit this nuclease and modulate the MAPK pathway, offering a multifaceted anti-inflammatory approach [15]. The onset of clinical disease is often exacerbated by concurrent viral infections, particularly with Infectious Bursal Disease Virus and avian influenza virus, or by environmental stressors such as ammonia exposure and overcrowding [2, 6]. Co-infection with Avian Pathogenic Escherichia coli (APEC) frequently results in severe airsacculitis and pericarditis, a condition historically termed CRD complex.

Clinical Signs and Gross Pathology

Typical clinical signs include rales, coughing, sneezing, nasal discharge, and conjunctivitis. In laying hens, egg production declines by 10% to 30%. Gross lesions consist of catarrhal tracheitis, perihepatitis, airsacculitis with foamy exudate, and fibrinous pericarditis when secondary bacterial invaders are present. Histologically, the tracheal mucosa shows lymphoid hyperplasia and diffuse infiltration of mononuclear cells.

Diagnostic Approaches

Accurate and timely diagnosis of MG is essential for implementing control measures. Detection methods fall into three main categories: serology, molecular diagnostics, and culture. The table below summarizes the principal diagnostic platforms.

Serological Testing

Serological screening is the backbone of flock-level monitoring. The serum plate agglutination (SPA) test is rapid and inexpensive but suffers from false positives due to cross-reactivity with other mycoplasmas and nonspecific agglutinins. The HI test offers greater specificity and is used for confirmatory testing. Commercial ELISA kits provide quantitative, high-throughput results and are widely employed in breeder flock surveillance. However, serology cannot differentiate vaccinated from infected birds unless DIVA (differentiating infected from vaccinated animals) strategies are applied, such as using recombinant vaccines lacking specific antigens.

Molecular Diagnostics

PCR-based methods offer superior sensitivity and the ability to differentiate strains. A duplex qPCR assay has been developed to distinguish wild-type MG from live vaccine strains (e.g., F-strain, ts-11, 6/85) by targeting unique genetic markers [4]. Another multiplex TaqMan real-time PCR assay enables simultaneous detection and differentiation of multiple MG strains [11]. For field deployment, a colorimetric LAMP assay using a rapid DNA extraction protocol has been validated, achieving a detection limit comparable to qPCR with a turnaround time under one hour [10]. Similarly, a recombinase-aided amplification combined with lateral-flow dipstick assay allows visual detection of MG without specialized equipment, making it suitable for point-of-care use [5]. These molecular tools are critical for confirming active infection and for monitoring vaccine shed and persistence.

Culture and Isolation

Mycoplasma culture requires specialized media (e.g., Frey's medium supplemented with swine serum, yeast extract, and antibiotics to inhibit contaminants). Colonies appear as fried-egg morphology after 3-7 days incubation at 37°C in 5% CO2. Culture is rarely used for routine diagnosis due to slow growth and low sensitivity but remains valuable for antimicrobial susceptibility testing and epidemiological typing.

Antimicrobial Therapy and Sensitivity

Antimicrobial treatment reduces clinical signs and transmission but does not eliminate MG from infected flocks. The most commonly used drugs are macrolides (tylosin, tilmicosin), fluoroquinolones (enrofloxacin), tetracyclines (oxytetracycline, doxycycline), and pleuromutilins (tiamulin, valnemulin). Increasing reports of antimicrobial resistance (AMR) in MG isolates have been documented [3]. The table below lists typical minimum inhibitory concentrations (MICs) for key antibiotics.

The pharmacokinetic/pharmacodynamic relationship of the novel pleuromutilin derivative APTM has been characterized, demonstrating favorable lung tissue penetration and sustained bactericidal activity against MG [12]. In practice, antimicrobials are administered via drinking water or feed, often during pullet rearing or around peak lay. However, antibiotic treatment in layer flocks raises concern about drug residues in eggs, and regulatory constraints on off-label use are tightening [3].

Vaccination

Vaccination is a cornerstone of MG control in multi-age commercial layers and breeders. Available vaccines include live attenuated strains (F-strain, ts-11, 6/85) and recombinant vector vaccines. A recombinant fowlpox virus expressing MG antigens has been evaluated in layer pullets, showing comparable protection to F-strain live vaccines with reduced reactogenicity and shedding [8]. The development of effective vaccines continues to be informed by detailed understanding of MG pathogenic mechanisms and immune evasion strategies [13]. Herbal medicine formulations have also been investigated for prophylactic and therapeutic use, with four Chinese herbal preparations showing efficacy in reducing clinical signs and MG load [1].

Control and Eradication in Breeder Flocks

Eradication of MG from primary breeder flocks is the most effective long-term strategy for reducing the economic impact of CRD. The approach relies on a combination of strict biosecurity, intensive surveillance, and depopulation of infected flocks. The decision-making process for eradication is illustrated in the following flowchart.

flowchart TD
    A[Start: Breeder flock monitoring], > B{Monthly serological screening (ELISA/HI)}
    B, >|Negative| C[Continue routine biosecurity]
    C, > B
    B, >|Positive| D{Confirm with PCR / culture}
    D, >|Wild-type MG detected| E[Quarantine affected houses]
    E, > F{Epidemiological investigation}
    F, >|Single house| G[Depopulate positive house]
    F, >|Multiple houses| H[Depopulate entire farm]
    G, > I[Cleaning, disinfection, down time]
    H, > I
    I, > J[Restock with MG-free pullets]
    J, > A
    D, >|Vaccine strain detected| K{Assess clinical impact}
    K, >|No disease| L[Continue monitoring]
    K, >|Breakthrough disease| M[Review vaccination program]
    M, > N[Adjust vaccine protocol or antimicrobial metaphylaxis]
    N, > A

Key components of an eradication program include:

• All-in/all-out production flow with complete depopulation between cycles.
• Multidirectional biosecurity barriers including dedicated footwear, equipment, and vehicle sanitation.
• Cage or floor management with strict separation of age groups.
• Sentinel bird programs using MG-free chickens to detect residual contamination after cleaning.
• Rodent and wild bird control, as several avian species can serve as mechanical vectors.
• Regular training of farm personnel on mycoplasma transmission risks.

Molecular typing of isolates using gene sequencing (e.g., mgc2, gapA, or whole genome sequencing) supports epidemiological tracking and confirmation of eradication success. Acoustic monitoring of chicken cough and respiratory sounds has also emerged as a non-invasive screening tool for early detection of respiratory disease, potentially augmenting conventional surveillance [7].

Conclusion

Mycoplasma gallisepticum remains a persistent challenge in the poultry industry, particularly in multi-age layer complexes and broiler breeder operations. The integration of high-specificity molecular assays (duplex qPCR, LAMP, RAA) with traditional serology allows precise diagnosis and strain differentiation. While antimicrobial therapy provides short-term clinical relief, the emergence of resistance underscores the need for judicious drug use and investment in effective vaccines. Elimination of MG from primary breeders through comprehensive surveillance and depopulation strategies is the most sustainable path to controlling CRD. Continued research into anti-inflammatory host-directed therapies, novel drug derivatives, and improved vaccine platforms will further refine the tools available for MG management.

References

1. Yan Y, Liao L, Fan Y, et al. Evaluation and Analysis of the Efficacy of Four Chinese Herbal Medicines and Formulations in Preventing and Treating Mycoplasma gallisepticum Infection in Chickens. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42191062/

2. Rodrigo CH, Kulappu Arachchige SN, Bushell RN, et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42190304/

3. Morrow CJ, Achari RA, Charles M, et al. Mycoplasma, antibiotics in lay, and antimicrobial resistance (AMR). Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42139894/

4. Fan P, Liu Z, Xu Y, et al. Strain-specific detection of Mycoplasma gallisepticum: A duplex qPCR assay for vaccine efficacy and infection surveillance. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42139893/

5. Xuan H, Wang S, Ren X, et al. Rapid visual detection of Mycoplasma gallisepticum by combining recombinase-aided amplification with lateral-flow dipstick assay. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42127851/

6. Hartady T, Sugandi SD, Viqih M. A Case of Avian Influenza Co-Infection and Multifactorial Diseases in a Broiler Chicken Farm in Majalengka, West Java, Indonesia. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42076736/

7. Guo X, Shi L, Li J, et al. Chicken disease detection and localization using multi-noise separation and acoustic recognition. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42056823/

8. Hashish A, Chaves M, Osemeke O, et al. Evaluation of Vaccination Programs in Layer Pullets Using Recombinant Fowl-Pox Mycoplasma gallisepticum Vaccine in Comparison to Commercially Available F-Strain Live Vaccines. Avian Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41973009/

9. Xu F, Bao L, Yao Y, et al. Mechanism of Scutellaria baicalensis extracellular vesicles in attenuating Mycoplasma gallisepticum-induced inflammation via TRPC1 - STIM1/ORAI1 channel inhibition. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41905072/

10. Mayne R, Pant SD, Huang J, et al. A field-ready colourimetric LAMP assay for detection of Mycoplasma gallisepticum using rapid DNA extraction. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41785617/

11. Xin J, Zhang J, Liang S, et al. A multiplex TaqMan real-time PCR assay for differential identification of wild-type and vaccine strains of Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41702344/

12. Yang W, Ding H, Ma X, et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41650639/

13. Chen J, Liu P, Chen Y. Pathogenic mechanisms and vaccine development for Mycoplasma gallisepticum in chickens. Front Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41602759/

14. Li X, Tian J, Zhou W, et al. Development and validation of a sensitive fluorescence RT-qPCR assay with TaqMan-MGB probe for detection of H6 subtype avian influenza A virus. J Vet Diagn Invest. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41562546/

15. Liu W, Wang S, Hu J, et al. Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41548475/